TY - JOUR
T1 - Effect of threshold growth as a major feature on LI-RADS categorization
AU - Chernyak, Victoria
AU - Kobi, Mariya
AU - Flusberg, Milana
AU - Fruitman, Kate C.
AU - Sirlin, Claude B.
N1 - Funding Information:
V. Chernyak, M. Kobi, M. Flusberg, K.C. Fruitman have no conflict of interest. C.B. Sirlin: Industry grant support—Siemens, GE, Guerbet; Consulting and service agreements—Bracco, Alexion, AstraZeneca, Bioclinica, BMS, Fibrogen, Galmed, Genentech, Genzyme, Gilead, Icon, Intercept, Isis, Janssen, NuSirt, Perspectum, Pfizer, Profil, Sanofi, Shire, Synageva, Tobira, Takeda, Virtual Scopics
Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Purpose: Liver Imaging Reporting and Data System (LI-RADS) uses major features (arterial phase hyperenhancement [APHE], “washout” [WO], “capsule,” diameter, threshold growth [TG]) to codify probability of hepatocellular carcinoma for each observation. This study assessed the effect of removing TG as a major feature on LI-RADS categorization. Materials and methods: In this HIPAA-compliant, IRB-approved study, all MR and CT clinical reports containing a standardized LI-RADS v2014 template between 4/15–1/17 were retrospectively reviewed for each LR-3, LR-4, and LR-5 reported observation. Two LI-RADS categories were then assigned: one using all LI-RADS major features and one after removing TG as a major feature. The two categories were compared descriptively. Results: The study included 265 patients (172 [65%] male, mean age 63 [±10] years) with 489 observations (median diameter 14 mm, IQR 10–20 mm), of which 345 (71%) had APHE, 307 (63%) had WO, 86 (18%) had “capsule,” and 72 (15%) had TG. Of 86 observations with TG, 47 (65%) were new observations ≥10 mm, 14 (19%) had diameter increase ≥50% in ≤6 months, and 11 (15%) had diameter increase ≥100% in >6 months. Using all major features, 214/489 (44%) observations were LR-3, 129/489 (26%) were LR-4, and 146/489 (30%) were LR-5. After removing TG, 237/489 (48%) were LR-3, 119/489 (24%) were LR-4, and 133 (27%) were LR-5. Removing TG caused a category downgrade for 35/489 (7%, 95% CI 5–10) observations, including 13/146 (9%, 95% CI 3–14) LR-5 observations. Conclusion: 9% of LR-5 observations would be downgraded without TG.
AB - Purpose: Liver Imaging Reporting and Data System (LI-RADS) uses major features (arterial phase hyperenhancement [APHE], “washout” [WO], “capsule,” diameter, threshold growth [TG]) to codify probability of hepatocellular carcinoma for each observation. This study assessed the effect of removing TG as a major feature on LI-RADS categorization. Materials and methods: In this HIPAA-compliant, IRB-approved study, all MR and CT clinical reports containing a standardized LI-RADS v2014 template between 4/15–1/17 were retrospectively reviewed for each LR-3, LR-4, and LR-5 reported observation. Two LI-RADS categories were then assigned: one using all LI-RADS major features and one after removing TG as a major feature. The two categories were compared descriptively. Results: The study included 265 patients (172 [65%] male, mean age 63 [±10] years) with 489 observations (median diameter 14 mm, IQR 10–20 mm), of which 345 (71%) had APHE, 307 (63%) had WO, 86 (18%) had “capsule,” and 72 (15%) had TG. Of 86 observations with TG, 47 (65%) were new observations ≥10 mm, 14 (19%) had diameter increase ≥50% in ≤6 months, and 11 (15%) had diameter increase ≥100% in >6 months. Using all major features, 214/489 (44%) observations were LR-3, 129/489 (26%) were LR-4, and 146/489 (30%) were LR-5. After removing TG, 237/489 (48%) were LR-3, 119/489 (24%) were LR-4, and 133 (27%) were LR-5. Removing TG caused a category downgrade for 35/489 (7%, 95% CI 5–10) observations, including 13/146 (9%, 95% CI 3–14) LR-5 observations. Conclusion: 9% of LR-5 observations would be downgraded without TG.
KW - Ancillary feature
KW - Hepatocellular carcinoma
KW - LI-RADS
KW - Major feature
KW - Threshold growth
UR - http://www.scopus.com/inward/record.url?scp=85016109612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016109612&partnerID=8YFLogxK
U2 - 10.1007/s00261-017-1105-8
DO - 10.1007/s00261-017-1105-8
M3 - Article
C2 - 28352950
AN - SCOPUS:85016109612
SN - 2366-004X
VL - 42
SP - 2089
EP - 2100
JO - Abdominal Radiology
JF - Abdominal Radiology
IS - 8
ER -